跳至主要内容
临床试验/CTRI/2025/04/083930
CTRI/2025/04/083930尚未招募3 期

A Randomized, Double-Blinded, Placebo-Controlled Clinical Study to evaluate the Safety and Efficacy of Rhodiola in Enhancing Physical, Mental and social wellbeing, in Physically Inactive elderly Adults.

Finzelberg GmbH and Co. KG,4 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2025年11月4日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
140
试验地点
4
主要终点
To assess the impact of Rhodiola on muscle mass (Anthropometry and BMI), muscle strength (Hand grip test), Bench Press, Leg Press, DOMS (Delayed onset muscle soreness) and Appendicular Skeletal Muscle Mass Index (ASMI).

研究概览

简要总结

This randomized double-blind placebo-controlled parallel clinical study will enroll 140 physically inactive adults aged 55 to 75 years into two equal groups of 70 participants each with an equal gender distribution. The study will span 15 months post-CTRI approval with each participant undergoing a 12-week intervention.

Inclusion Criteria: Eligible participants must be physically inactive with less than 150 minutes per week of moderate-intensity activity and no resistance training, postmenopausal for females, and exhibit early symptoms of muscle weakness with a SARC-F score of 4 or more and reduced muscle mass via BIA. Fatigue defined by a Chalder Fatigue Scale score of 4 or more, limited physical performance with gait speed less than 1 meter per second, BMI between 18 and 35, and a body weight of at least 50 kilograms are required.

Exclusion Criteria: Conditions causing fatigue, muscle loss, or weight reduction such as congestive cardiac failure, chronic kidney disease, cancer, and COPD, hs-CRP greater than 3 milligrams per liter, psychiatric disorders, smoking, alcohol use, uncontrolled diabetes with HbA1c greater than 10, and recent supplement use, surgery, or clinical study participation.

Endpoints: Primary outcomes include muscle mass, strength measured through grip test, bench press, leg press, and appendicular skeletal muscle mass index, and endurance measured through a six-minute walk and sit-stand test. Secondary endpoints assess lean body mass, VO2 max, quality of life using SF-36, fatigue using the Chalder Fatigue Scale, stress using the Perceived Stress Scale, sleep using the Jenkins Sleep Scale, balance using the Single-Leg Test, wellness using the Perceived Wellness Survey, social engagement using the Self-Efficacy for Social Participation Scale, and biomarkers including hsCRP and testosterone. Safety assessments include vitals, ECG, and blood parameters.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant and Investigator Blinded

入排标准

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

To assess the impact of Rhodiola on muscle mass (Anthropometry and BMI), muscle strength (Hand grip test), Bench Press, Leg Press, DOMS (Delayed onset muscle soreness) and Appendicular Skeletal Muscle Mass Index (ASMI).

时间窗: Baseline, 8 weeks and 12 weeks

To evaluate the improvement in energy levels by measuring gait speed, chair stand test, Walking Capacity, measured as distance or speed, tested via a 6-minute walk test and 30-second sit-stand.

时间窗: Baseline, 8 weeks and 12 weeks

次要结局

  • 1. To measure Lean Body Mass (LBM)(2. To evaluate the improvement in energy levels by measuring VO2 max through Treadmill test for those participants who will be able to do Treadmill test)

研究者

发起方
Finzelberg GmbH and Co. KG,
申办方类型
Pharmaceutical industry-Global

研究点 (4)

Loading locations...

相似试验